Q3 EPS Estimates for Teladoc Health Boosted by Analyst

Key Points

• Zacks Research has upgraded its Q3 2025 earnings per share (EPS) estimate for Teladoc Health from ($0.25) to ($0.24).
• Teladoc reported a Q2 EPS of ($0.19), beating the consensus estimate of ($0.27) by $0.08, while revenue for the quarter was $631.90 million, slightly above expectations.
• Several financial institutions have recently lowered their price targets for Teladoc, with a consensus average rating of "Hold" and an average price target of $9.76.

Teladoc Health, Inc. (NYSE:TDOC - Free Report) - Equities researchers at Zacks Research lifted their Q3 2025 earnings per share (EPS) estimates for shares of Teladoc Health in a research note issued on Tuesday, August 12th. Zacks Research analyst R. Department now anticipates that the health services provider will post earnings per share of ($0.24) for the quarter, up from their previous forecast of ($0.25). The consensus estimate for Teladoc Health's current full-year earnings is ($1.16) per share. Zacks Research also issued estimates for Teladoc Health's Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.29) EPS, Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.93) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.92) EPS.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC restated a "hold" rating on shares of Teladoc Health in a research note on Thursday, May 1st. Evercore ISI boosted their price objective on Teladoc Health from $7.00 to $8.00 and gave the company an "in-line" rating in a report on Wednesday, July 9th. Bank of America lowered their price objective on Teladoc Health from $8.00 to $7.00 and set a "neutral" rating for the company in a report on Wednesday, May 28th. Wells Fargo & Company lowered their target price on Teladoc Health from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. Finally, Truist Financial reduced their price objective on Teladoc Health from $10.00 to $9.00 and set a "hold" rating for the company in a research report on Tuesday, May 27th. Twelve research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $9.76.

Teladoc Health Trading Up 2.9%

Teladoc Health stock traded up $0.21 during midday trading on Thursday, reaching $7.51. The stock had a trading volume of 5,729,024 shares, compared to its average volume of 7,944,137. Teladoc Health has a twelve month low of $6.35 and a twelve month high of $15.21. The stock has a market capitalization of $1.33 billion, a PE ratio of -6.31 and a beta of 1.76. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.58 and a current ratio of 2.67. The stock's 50-day simple moving average is $7.72 and its 200 day simple moving average is $8.31.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The health services provider reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.08. The company had revenue of $631.90 million during the quarter, compared to the consensus estimate of $621.91 million. Teladoc Health had a negative return on equity of 10.13% and a negative net margin of 8.16%. Teladoc Health's revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.38) earnings per share.

Institutional Investors Weigh In On Teladoc Health

Large investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. boosted its holdings in Teladoc Health by 60.8% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 39,738 shares of the health services provider's stock valued at $316,000 after acquiring an additional 15,030 shares during the period. Golden State Wealth Management LLC lifted its stake in shares of Teladoc Health by 102.6% in the first quarter. Golden State Wealth Management LLC now owns 3,337 shares of the health services provider's stock valued at $27,000 after buying an additional 1,690 shares during the period. Wedmont Private Capital raised its position in Teladoc Health by 20.3% in the first quarter. Wedmont Private Capital now owns 16,086 shares of the health services provider's stock worth $117,000 after purchasing an additional 2,715 shares in the last quarter. Geode Capital Management LLC raised its position in Teladoc Health by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 3,947,831 shares of the health services provider's stock worth $35,894,000 after purchasing an additional 22,664 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of Teladoc Health by 22.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 14,725 shares of the health services provider's stock worth $134,000 after buying an additional 2,662 shares in the last quarter. 76.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Adam C. Vandervoort sold 5,808 shares of the business's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $6.86, for a total transaction of $39,842.88. Following the sale, the insider directly owned 69,773 shares of the company's stock, valued at $478,642.78. The trade was a 7.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Carlos Nueno sold 3,958 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $6.86, for a total transaction of $27,151.88. Following the completion of the transaction, the insider directly owned 17,645 shares in the company, valued at $121,044.70. This trade represents a 18.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,656 shares of company stock valued at $128,189 in the last three months. 0.58% of the stock is currently owned by company insiders.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.